Robert Dreicer, MD, MS, MACP, FASCO, presented “Perioperative Chemotherapy for Upper Tract Urothelial Cancer” at the 7th International Bladder Cancer Update on December 6, 2024, in Dallas, Texas.
How to cite: Dreicer, Robert. “Perioperative Chemotherapy for Upper Tract Urothelial Cancer” December 2024. Accessed Mar 2025. https://grandroundsinurology.com/perioperative-chemotherapy-for-upper-tract-urothelial-cancer/
Perioperative Chemotherapy for Upper Tract Urothelial Cancer – Summary
Robert Dreicer, MD, MS, MACP, FASCO, highlights the complexities of managing high-grade urothelial carcinoma of the upper tract. In this 10-minute presentation, he presents a case of a 68-year-old man with hematuria who is found to have a 2.5 cm mass at the left UPJ. After undergoing a left nephroureterectomy, pathology confirms invasive high-grade disease with lymph node involvement.
Dr. Dreicer underscores the historical challenge of interdisciplinary care in urothelial cancer management and transitions to the historical evidence for chemotherapy in urothelial cancer. He references the POUT trial, demonstrating a disease-free survival benefit with adjuvant chemotherapy.
This case illustrates the challenges in real-world decision-making, where varying recommendations reflect ongoing debates about adjuvant strategies. The talk reinforces the necessity of early multidisciplinary planning to maximize treatment opportunities.
About the 7th International Bladder Cancer Update:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Robert Dreicer, MD, MS, MACP, FASCO, is the Associate Director for Clinical Research and the Deputy Director of the University of Virginia Comprehensive Cancer Center in Charlottesville, Virginia. He serves as Section Head of Medical Oncology and Co-Director of the Paul Mellon Urologic Institute. He is also a Professor of Medicine and Urology at the University of Virginia School of Medicine. He previously served as Chair of the Department of Solid Tumor Oncology at the Cleveland Clinic. Dr. Dreicer is board-certified in internal medicine and oncology and he specializes in the management of genitourinary malignancies, as well as the design and conduct of clinical trials in urologic oncology. Dr. Dreicer received his BS from Colorado State University and his MS from the University of Texas Graduate School of Biomedical Science in Houston, Texas. He received his MD from the University of Texas Medical School in Houston before completing an internal medicine residency at Indiana University in Indianapolis. He then went on to a medical oncology fellowship at the University of Wisconsin Carbone Clinical Cancer Center in Madison, Wisconsin. Dr. Dreicer has published widely in genitourinary oncology and served as principal investigator of a large number of studies in genitourinary neoplasms. He served as Co-chair of the National Cancer Institute Genitourinary (NCI GU) Steering Committee from 2012-2018 and is a member of the editorial board of the New England Journal of Medicine Journal Watch Hematology/Oncology and the American Board of Internal Medicine (ABIM) Medical Oncology Longitudinal Test Assessment Committee.
